Bionano Genomics Inc. [NASDAQ: BNGO] stock went on a downward path that fall over -2.89% on Friday, amounting to a one-week price decrease of less than -28.30%. The company report on February 26, 2021 that Bionano’s Saphyr Data Prove Essential in Creating the Most Comprehensive, Ethnically Diverse Collection of Genome Variation Ever Completed.
Article published in Science reveals that optical genome mapping uniquely makes thousands of large structural variant calls.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication in Science of a study by the Human Genome Structural Variation Consortium (HGSVC) that used a combination of advanced sequencing and optical genome mapping (OGM) with Saphyr to assemble with high resolution and structural accuracy 64 haplotype-resolved human genomes from 32 individuals representing 25 different populations. The peer-reviewed publication, which previously appeared on the pre-print server bioRxiv, builds on the original Human Genome Project to better capture genetic diversity by cataloging both single nucleotide variations (SNVs) and structural variations (SVs) from each individual reference-quality genome assembly compared to the standard human genome reference. The resulting assemblies and catalog of SNVs and SVs can serve as a diversity panel that researchers and clinicians can use to accelerate the discovery of new therapeutic targets and pathogenic genetic variations by making it easier and faster to filter out variation that is representative of population diversity. They further enable population-specific studies on genetic predispositions to human diseases as well as the potential discovery of more complex forms of genetic variation.
Over the last 12 months, BNGO stock rose by 924.21%. The one-year Bionano Genomics Inc. stock forecast points to a potential upside of 11.06. The average equity rating for BNGO stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.82 billion, with 271.83 million shares outstanding and 151.94 million shares in the current float. Compared to the average trading volume of 86.67M shares, BNGO stock reached a trading volume of 26459776 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Bionano Genomics Inc. [BNGO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNGO shares is $10.94 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNGO stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 24, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on April 08, 2020, representing the official price target for Bionano Genomics Inc. stock.
The Average True Range (ATR) for Bionano Genomics Inc. is set at 1.71, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 249.37. The Price to Book ratio for the last quarter was 88.45, with the Price to Cash per share for the same quarter was set at 0.10.
BNGO Stock Performance Analysis:
Bionano Genomics Inc. [BNGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.30. With this latest performance, BNGO shares dropped by -11.87% in over the last four-week period, additionally plugging by 1391.42% over the last 6 months – not to mention a rise of 924.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 46.38, with the RSI for the last a single of trading hit 39.98, and the three-weeks RSI is set at 50.64 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 7.80, while it was recorded at 10.60 for the last single week of trading, and 2.38 for the last 200 days.
Insight into Bionano Genomics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -255.44 and a Gross Margin at +22.46. Bionano Genomics Inc.’s Net Margin is presently recorded at -294.34.
Return on Total Capital for BNGO is now -120.73, given the latest momentum, and Return on Invested Capital for the company is -261.76. Return on Equity for this stock declined to -433.64, with Return on Assets sitting at -108.40. When it comes to the capital structure of this company, Bionano Genomics Inc. [BNGO] has a Total Debt to Total Equity ratio set at 555.80. Additionally, BNGO Total Debt to Total Capital is recorded at 84.75, with Total Debt to Total Assets ending up at 66.49.
Reflecting on the efficiency of the workforce at the company, Bionano Genomics Inc. [BNGO] managed to generate an average of -$307,372 per employee. Receivables Turnover for the company is 1.87 with a Total Asset Turnover recorded at a value of 0.37.Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.
BNGO Stock EPS
With the latest financial reports released by the company, Bionano Genomics Inc. posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -66.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BNGO.
Bionano Genomics Inc. [BNGO] Insider Position Details
There are presently around $121 million, or 6.90% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: VANGUARD GROUP INC with ownership of 7,132,899, which is approximately 28.144% of the company’s market cap and around 0.06% of the total institutional ownership; PURA VIDA INVESTMENTS, LLC, holding 2,100,000 shares of the stock with an approximate value of $20.43 million in BNGO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $9.19 million in BNGO stock with ownership of nearly 53.309% of the company’s market capitalization.
Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 36 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 5,122,131 shares. Additionally, 13 investors decreased positions by around 1,278,012 shares, while 5 investors held positions by with 6,083,937 shares. The mentioned changes placed institutional holdings at 12,484,080 shares, according to the latest SEC report filing. BNGO stock had 26 new institutional investments in for a total of 3,064,370 shares, while 7 institutional investors sold positions of 1,085,347 shares during the same period.